Gottlieb On Gene Therapies: 'Very Seductive' To Think About Accelerated Approval Pathway

Accelerated approval would help agency monitor gene therapies for durability and off-target effects, US FDA commissioner says.

Genetic Medicine with dna isolated on white.3d rendering

As the US FDA plans to release guidance clarifying its approach for regulating gene therapies, agency Commissioner Scott Gottlieb provided some insight into the agency's thinking on the subject when he called it "very seductive" to think about the accelerated approval pathway for such therapies.

Speaking at the Reagan-Udall Foundation's annual meeting May 4, Gottlieb stressed that the most critical questions in the review of gene therapy are about the durability of the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Review Pathways

More from Pathways & Standards

Tougher Approval Standards May Follow Vinay Prasad’s Appointment To Lead US FDA’s CBER

 

Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By 

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By 

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.